Endocannabinoid Metabolism and Synaptic Function

内源性大麻素代谢和突触功能

基本信息

  • 批准号:
    10322050
  • 负责人:
  • 金额:
    $ 38.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-02-05 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

Summary The long-term goal of this research project is to understand cellular, molecular, and epigenetic mechanisms of endocannabinoid (eCB) signaling that may modulate synaptic and neurocognitive functions. While the eCB system is known to play an important role in regulation of brain homeostasis, accumulated information suggests that the eCB system is also involved in several mental and neurological disorders. Augmentation of eCB signaling by inhibition of eCB metabolism has been proposed as a promising therapy for treatment and prevention of mental and neurocognitive illnesses. However, our understanding of the mechanisms underlying augmentation of eCB signaling by chronic inhibition of eCB metabolism in synaptic activity is still limited. Strengthening endocannabinoid 2-arachidonoylglycerol (2-AG) signaling by chronic inactivation of monoacylglycerol lipase (MAGL), the primary enzyme that hydrolyzes 2-AG in the brain, has been shown to produce antidepressant- and anxiolytic-like effects and enhance hippocampal synaptic plasticity as well as learning and memory. Our recent studies showed that sustained inactivation of MAGL increases the density of dendritic spines and expression of glutamate receptor subunits in the hippocampus. This suggests that augmentation of 2-AG signaling by inhibition of MAGL regulates structural and functional plasticity of synapses that determine activity of neural circuits and corresponding neurocognitive functions. MicroRNAs (miRNAs) are small noncoding RNAs that negatively regulate expression and function of target molecules. However, we do not know whether miRNAs that target molecules involved in maintaining the integrity of synaptic structure and function are regulated by eCB signaling. In the proposed studies, we will test the hypothesis that regulation of synaptic activity and cognitive function by chronic inactivation of MAGL is through 2-AG signaling-mediated suppression of the miRNA that targets the molecules important for regulation of synaptic activity. The research proposed in this application is expected to further our understanding of the mechanisms underlying augmentation of eCB signaling in regulation of synaptic and neurocognitive functions, which may lead to future research on improving strategies for the treatment and prevention of mental and neurological illnesses.
概括 该研究项目的长期目标是了解细胞、分子和表观遗传机制 内源性大麻素 (eCB) 信号传导可调节突触和神经认知功能。虽然欧洲央行 众所周知,该系统在调节大脑稳态、积累信息方面发挥着重要作用 表明 eCB 系统还与多种精神和神经系统疾病有关。增强 通过抑制 eCB 代谢的 eCB 信号传导已被提议作为一种有前途的治疗方法 预防精神和神经认知疾病。然而,我们对潜在机制的理解 通过长期抑制突触活动中的 eCB 代谢来增强 eCB 信号传导仍然有限。 通过长期失活增强内源性大麻素 2-花生四烯酰甘油 (2-AG) 信号传导 单酰基甘油脂肪酶 (MAGL) 是大脑中水解 2-AG 的主要酶,已被证明可以 产生抗抑郁和抗焦虑样作用,增强海马突触可塑性以及 学习和记忆。我们最近的研究表明,MAGL 的持续失活会增加 树突棘和海马谷氨酸受体亚基的表达。这表明 通过抑制 MAGL 增强 2-AG 信号传导调节突触的结构和功能可塑性 决定神经回路的活动和相应的神经认知功能。微小RNA (miRNA) 是 负调控靶分子表达和功能的小非编码 RNA。然而,我们做 不知道靶向分子的 miRNA 是否参与维持突触结构的完整性和 功能受 eCB 信号调节。在拟议的研究中,我们将检验以下假设:监管 MAGL 慢性失活通过 2-AG 信号传导介导突触活动和认知功能 抑制针对突触活性调节重要分子的 miRNA。研究 本申请中提出的建议有望进一步加深我们对潜在机制的理解 增强 eCB 信号在突触和神经认知功能的调节中的作用,这可能会导致未来 关于改进精神和神经疾病治疗和预防策略的研究。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.
  • DOI:
    10.1016/j.pharmthera.2023.108394
  • 发表时间:
    2023-04
  • 期刊:
  • 影响因子:
    13.5
  • 作者:
    Chen, Chu
  • 通讯作者:
    Chen, Chu
Endocannabinoid Metabolism and Traumatic Brain Injury.
  • DOI:
    10.3390/cells10112979
  • 发表时间:
    2021-11-02
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Zhu D;Gao F;Chen C
  • 通讯作者:
    Chen C
Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.
星形胶质细胞中 2-花生四烯酰甘油信号传导的增强可通过调节 miRNA-30b 维持突触功能。
  • DOI:
    10.1016/j.expneurol.2022.114292
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Zhu,Dexiao;Zhang,Jian;Gao,Fei;Hu,Mei;Hashem,Jack;Chen,Chu
  • 通讯作者:
    Chen,Chu
Endocannabinoid control of neuroinflammation in traumatic brain injury by monoacylglycerol lipase in astrocytes.
  • DOI:
    10.4103/1673-5374.355755
  • 发表时间:
    2023-05
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Chen C
  • 通讯作者:
    Chen C
Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease.
  • DOI:
    10.1007/s12035-021-02400-2
  • 发表时间:
    2021-08
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    Hashem J;Hu M;Zhang J;Gao F;Chen C
  • 通讯作者:
    Chen C
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHU CHEN其他文献

CHU CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHU CHEN', 18)}}的其他基金

Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease
沉默星形细胞 MAGL 作为阿尔茨海默病的治疗方法
  • 批准号:
    10633381
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Traumatic brain injury and Alzheimer's disease
创伤性脑损伤和阿尔茨海默病
  • 批准号:
    10347330
  • 财政年份:
    2019
  • 资助金额:
    $ 38.75万
  • 项目类别:
Endocannabinoid Metabolism and Synaptic Function
内源性大麻素代谢和突触功能
  • 批准号:
    9929317
  • 财政年份:
    2019
  • 资助金额:
    $ 38.75万
  • 项目类别:
Endocannabinoid Metabolism and Synaptic Function
内源性大麻素代谢和突触功能
  • 批准号:
    9522674
  • 财政年份:
    2018
  • 资助金额:
    $ 38.75万
  • 项目类别:
Endocannabinoid Metabolism and Synaptic Function
内源性大麻素代谢和突触功能
  • 批准号:
    10056223
  • 财政年份:
    2018
  • 资助金额:
    $ 38.75万
  • 项目类别:
FFPE Validation of a Survival Gene Signature in HPV-Negative Oral Cavity Cancer
HPV 阴性口腔癌生存基因特征的 FFPE 验证
  • 批准号:
    8986780
  • 财政年份:
    2015
  • 资助金额:
    $ 38.75万
  • 项目类别:
FFPE Validation of a Survival Gene Signature in HPV-Negative Oral Cavity Cancer
HPV 阴性口腔癌生存基因特征的 FFPE 验证
  • 批准号:
    9197967
  • 财政年份:
    2015
  • 资助金额:
    $ 38.75万
  • 项目类别:
Infrastructure Support and Pilot Tissue Collection for the CARET Biorepository
CARET 生物样本库的基础设施支持和试点组织采集
  • 批准号:
    9882960
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Endocannabinoids in Neurodegenerative Diseases
神经退行性疾病中的内源性大麻素
  • 批准号:
    9919000
  • 财政年份:
    2012
  • 资助金额:
    $ 38.75万
  • 项目类别:
Endocannabinoids in Neurodegenerative Diseases
神经退行性疾病中的内源性大麻素
  • 批准号:
    8370186
  • 财政年份:
    2012
  • 资助金额:
    $ 38.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了